{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T18:49:50Z","timestamp":1694630990877},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2003,6,1]],"date-time":"2003-06-01T00:00:00Z","timestamp":1054425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2003,6,1]],"date-time":"2003-06-01T00:00:00Z","timestamp":1054425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2003,6]]},"DOI":"10.1007\/s11864-003-0026-7","type":"journal-article","created":{"date-parts":[[2007,6,28]],"date-time":"2007-06-28T08:38:37Z","timestamp":1183019917000},"page":"247-258","source":"Crossref","is-referenced-by-count":4,"title":["Myeloma: Update on supportive care strategies"],"prefix":"10.1007","volume":"4","author":[{"given":"Jes\u00fas F. San","family":"Miguel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram\u00f3n","family":"Garc\u00eda-Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"26_CR1","first-page":"36","volume":"84","author":"Miguel JF San","year":"1999","unstructured":"San Miguel JF, Blade J, Garc\u00eda-Sanz R: Treatment of multiple myeloma. Haematologica 1999, 84:36\u201358.","journal-title":"Haematologica"},{"key":"26_CR2","unstructured":"San Miguel JF: Supportive therapy for complications in multiple myeloma. In Education Sessions of the Second Meeting of the European Haematology Association, 1996. Blackwell Science Ltd; 1996:12-16."},{"issue":"Suppl 1","key":"26_CR3","first-page":"S29","volume":"15","author":"Miguel JF San","year":"1998","unstructured":"San Miguel JF, Garc\u00eda-Sanz R: Recombinant human erythropoietin in the anaemia of multiple myeloma and non-Hodgkin\u2019s lymphoma. Med Oncol 1998, 15(Suppl 1):S29-S34.","journal-title":"Med Oncol"},{"key":"26_CR4","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1182\/blood.V99.4.1305","volume":"99","author":"F Silvestris","year":"2002","unstructured":"Silvestris F, Cafforio P, Tucci M, Dammacco F: Negative regulation of erythroblast maturation by Fas-L+\/ TRAIL+ highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma. Blood 2002, 99:1305\u20131313.","journal-title":"Blood"},{"key":"26_CR5","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1001\/archinte.155.19.2069","volume":"155","author":"JP Garton","year":"1995","unstructured":"Garton JP, Gertz MA, Witzig TE, et al.: Epoietin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled double blind trial. Arch Intern Med 1995, 155:2069\u20132074.","journal-title":"Arch Intern Med"},{"key":"26_CR6","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1182\/blood.V86.12.4446.bloodjournal86124446","volume":"86","author":"M Cazzola","year":"1995","unstructured":"Cazzola M, Messinger D, Battistel V, et al.: Recombinant human erythropoietin in the anemia associated with multiple myeloma and non-Hodgkin\u2019s lymphoma: dose finding and identification of predictors of response. Blood 1995, 86:4446\u20134453.","journal-title":"Blood"},{"key":"26_CR7","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/blood.V87.7.2675.bloodjournal8772675","volume":"87","author":"A Osterborg","year":"1996","unstructured":"Osterborg A, Boogaerts MA, Cimino R, et al.: Recombinant human erythropoietin in transfusiondependent patients with multiple myeloma and non-Hodgkin\u2019s lymphoma: a randomized multicenter study. The European Study Group of Erythropoietin (Epoietin Beta) Treatment in Multiple Myeloma and Non-Hodgkin\u2019s Lymphoma. Blood 1996, 87:2675\u20132682.","journal-title":"Blood"},{"key":"26_CR8","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2001.19.11.2865","volume":"19","author":"TJ Littlewood","year":"2001","unstructured":"Littlewood TJ, Bajetta E, Nortier JW, et al.: Effects of epoietin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001, 19:2865\u20132874.","journal-title":"J Clin Oncol"},{"key":"26_CR9","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1046\/j.1365-2141.2001.02715.x","volume":"113","author":"F Dammacco","year":"2001","unstructured":"Dammacco F, Castoldi G, Rodjer S: Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 2001, 113:172\u2013179.","journal-title":"Br J Haematol"},{"key":"26_CR10","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1200\/JCO.2002.08.131","volume":"20","author":"A Osterborg","year":"2002","unstructured":"Osterborg A, Brandberg Y, Molostova V, et al.: Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematological malignancies. J Clin Oncol 2002, 20:2486\u20132494. Randomized studies that have shown the advantage (eg, hemoglobin increase and reduction of transfusions) of treating MM with recombinant human EPO versus no treatment.","journal-title":"J Clin Oncol"},{"key":"26_CR11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/sj.thj.6200160","volume":"3","author":"H Ludwig","year":"2002","unstructured":"Ludwig H, Rai K, Blade J, et al.: Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations. Hematol J 2002, 3:121\u2013130.","journal-title":"Hematol J"},{"key":"26_CR12","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1182\/blood-2002-06-1767","volume":"100","author":"JD Rizzo","year":"2002","unstructured":"Rizzo JD, Lichtin AE, Woolf SH, et al.: Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002, 100:2303\u20132320. Recommendations from two expert panels to define the use of rHuEPO in anemic patients with cancer, including patients with MM.","journal-title":"Blood"},{"issue":"Suppl 1","key":"26_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1054\/bjoc.2001.1746","volume":"84","author":"JC Egrie","year":"2001","unstructured":"Egrie JC, Browne JK: Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001, 84(Suppl 1):3\u201310.","journal-title":"Br J Cancer"},{"key":"26_CR14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1046\/j.1365-2141.2002.03774.x","volume":"119","author":"M Hedenus","year":"2002","unstructured":"Hedenus M, Hansen S, Taylor K, et al.: Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br J Haematol 2002, 119:79\u201386.","journal-title":"Br J Haematol"},{"key":"26_CR15","doi-asserted-by":"crossref","first-page":"4248","DOI":"10.1182\/blood.V89.12.4248","volume":"89","author":"M Cazzola","year":"1997","unstructured":"Cazzola M, Mercuriali F, Brugnara C: Use of recombinant human erythropoietin outside the setting of uremia. Blood 1997, 89:4248\u20134267.","journal-title":"Blood"},{"key":"26_CR16","doi-asserted-by":"publisher","first-page":"5181","DOI":"10.1073\/pnas.081275298","volume":"98","author":"M Mittelman","year":"2001","unstructured":"Mittelman M, Neumann D, Peled A, et al.: Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci U S A 2001, 98:5181\u20135186.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"26_CR17","unstructured":"http:\/\/home.intekom.com\/pharm\/janssen\/eprex.html. Accessed February 11, 2003."},{"key":"26_CR18","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1136\/jcp.48.3.260","volume":"48","author":"RM Hargreaves","year":"1995","unstructured":"Hargreaves RM, Lea JR, Griffiths H, et al.: Immunological factors and risk of infection in plateau phase myeloma. J Clin Pathol 1995, 48:260\u2013266.","journal-title":"J Clin Pathol"},{"key":"26_CR19","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1046\/j.1365-2141.2001.02487.x","volume":"112","author":"AB Fassas","year":"2001","unstructured":"Fassas AB, Bolanos-Meade J, Buddharaju LN, et al.: Cytomegalovirus infection and non-neutropenic fever after autologous stem cell transplantation: high rates of reactivation in patients with multiple myeloma and lymphoma. Br J Haematol 2001, 112:1032\u20131033.","journal-title":"Br J Haematol"},{"key":"26_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1086\/313592","volume":"30","author":"O Lortholary","year":"2000","unstructured":"Lortholary O, Ascioglu S, Moreau P, et al.: Invasive aspergillosis as an opportunistic infection in nonallografted patients with multiple myeloma: a European Organization for Research and Treatment of Cancer\/ Invasive Fungal Infections Cooperative Group and the Intergroupe Francais du Myeloma. Clin Infect Dis 2000, 30:41\u201346.","journal-title":"Clin Infect Dis"},{"key":"26_CR21","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00282-997-0223-0","volume":"39","author":"C Vallejo","year":"1997","unstructured":"Vallejo C, Caballero MD, Garc\u00eda-Sanz R, et al.: Sequential intravenous-oral ciprofloxacin plus amoxycillin\/ clavulanic acid shortens hospital stay in infected non-severe neutropenic patients. Hematol Cell Ther 1997, 39:223\u2013227.","journal-title":"Hematol Cell Ther"},{"key":"26_CR22","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/S0002-9343(95)00043-7","volume":"100","author":"MM Oken","year":"1996","unstructured":"Oken MM, Pomeroy C, Weisdorf D, Bennett JM: Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Am J Med 1996, 100:624\u2013628.","journal-title":"Am J Med"},{"key":"26_CR23","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/sj.bmt.1701641","volume":"23","author":"P Ljungman","year":"1999","unstructured":"Ljungman P: Immunization of transplant recipients. Bone Marrow Transplant 1999, 23:635\u2013636.","journal-title":"Bone Marrow Transplant"},{"key":"26_CR24","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/S0140-6736(94)90180-5","volume":"343","author":"HM Chapel","year":"1994","unstructured":"Chapel HM, Lee M, Hargreaves R, et al.: Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet 1994, 343:1059\u20131063.","journal-title":"Lancet"},{"key":"26_CR25","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1001\/archinte.150.8.1693","volume":"150","author":"R Alexanian","year":"1990","unstructured":"Alexanian R, Barlogie B, Dixon D: Renal failure in multiple myeloma: pathogenesis and prognostic implications. Arch Intern Med 1990, 150:1693\u20131695.","journal-title":"Arch Intern Med"},{"key":"26_CR26","first-page":"32","volume":"4","author":"Miguel JF San","year":"1996","unstructured":"San Miguel JF: Supportive therapy for multiple myeloma. Trends Oncol Hematol 1996, 4:32\u201333.","journal-title":"Trends Oncol Hematol"},{"key":"26_CR27","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/j.1365-2141.1995.tb05400.x","volume":"91","author":"R Torra","year":"1995","unstructured":"Torra R, Blade J, Cases A, et al.: Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 1995, 91:854\u2013859.","journal-title":"Br J Haematol"},{"key":"26_CR28","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1001\/archinte.158.17.1889","volume":"158","author":"J Blade","year":"1998","unstructured":"Blade J, Fernandez-Llama P, Bosch F, et al.: Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998, 158:1889\u20131893.","journal-title":"Arch Intern Med"},{"key":"26_CR29","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/sj.thj.6200003","volume":"1","author":"Miguel JF San","year":"2000","unstructured":"San Miguel JF, Lahuerta JJ, Garc\u00eda-Sanz R, et al.: Are myeloma patients with renal failure candidates for autologous stem cell transplantation?\n                           Hematol J 2000, 1:28\u201336.","journal-title":"Hematol J"},{"key":"26_CR30","first-page":"947","volume":"2","author":"G Tricot","year":"1996","unstructured":"Tricot G, Alberts DS, Johnson CH, et al.: Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res 1996, 2:947\u2013952.","journal-title":"Clin Cancer Res"},{"key":"26_CR31","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1001\/archinte.154.17.1935","volume":"154","author":"R Gucalp","year":"1994","unstructured":"Gucalp R, Theriault R, Gill I, et al.: Treatment of cancerassociated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone. Arch Intern Med 1994, 154:1935\u20131944.","journal-title":"Arch Intern Med"},{"key":"26_CR32","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/bjc.1995.502","volume":"72","author":"OP Purohit","year":"1995","unstructured":"Purohit OP, Radstone CR, Anthony A, et al.: A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcemia of malignancy. Br J Cancer 1995, 72:1289\u20131293.","journal-title":"Br J Cancer"},{"key":"26_CR33","unstructured":"Major P, Lortholary A, Hon J, et al.: Zoledronic acid is better than pamidronate in the treatment of hypercalcemia of malignancy: a grouped analysis [abstract].\n                           Paper presented at the 36th Annual Meeting of American Society of Clinical Oncology. New Orleans, LA, May 20\u201323, 2000."},{"key":"26_CR34","unstructured":"British Columbia Cancer Agency Drug Index for Professionals: Pamidronate. http:\/\/www.bccancer.bc.ca\/HPI\/ DrugDatabase\/DrugIndexALPro\/Pamidronate.htm. Accessed February 11, 2003."},{"key":"26_CR35","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1200\/JCO.1993.11.8.1618","volume":"11","author":"SR Nussbaum","year":"1993","unstructured":"Nussbaum SR, Warrell RP Jr, Rude R, et al.: Doseresponse study of alendronate sodium for the treatment of cancer-associated hypercalcemia. J Clin Oncol 1993, 11:1618\u20131623.","journal-title":"J Clin Oncol"},{"key":"26_CR36","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.1996.14.1.268","volume":"14","author":"M Pecherstorfer","year":"1996","unstructured":"Pecherstorfer M, Herrmann Z, Body JJ, et al.: Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol 1996, 14:268\u2013276.","journal-title":"J Clin Oncol"},{"key":"26_CR37","unstructured":"Cancer Pain Relief. Geneva: World Health Organization; 1996."},{"issue":"Suppl 2","key":"26_CR38","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1002\/1097-0142(20000615)88:12+<2940::AID-CNCR10>3.0.CO;2-W","volume":"88","author":"JH Healey","year":"2000","unstructured":"Healey JH, Brown HK: Complications of bone metastases: surgical management. Cancer 2000, 88(Suppl 2):2940\u20132951.","journal-title":"Cancer"},{"key":"26_CR39","first-page":"56","volume":"9","author":"SA Levine","year":"2000","unstructured":"Levine SA, Perin LA, Hayes D, Hayes WS: An evidencebased evaluation of percutaneous vertebroplasty. Manag Care 2000, 9:56\u201360, 63.","journal-title":"Manag Care"},{"key":"26_CR40","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1200\/JCO.2002.09.097","volume":"20","author":"S Dudeney","year":"2002","unstructured":"Dudeney S, Lieberman IH, Reinhardt MK, Hussein M: Kyphoplasty in the treatment of osteolytic vertebral compression fractures as a result of multiple myeloma. J Clin Oncol 2002, 20:2382\u20132387. This is a new surgical procedure for treatment of vertebral compressive fractures in patients with MM.","journal-title":"J Clin Oncol"},{"key":"26_CR41","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1200\/JCO.1991.9.8.1397","volume":"9","author":"AR Belch","year":"1991","unstructured":"Belch AR, Bergsagel DE, Wilson K, et al.: Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 1991, 9:1397\u20131402.","journal-title":"J Clin Oncol"},{"key":"26_CR42","first-page":"449","volume":"2","author":"A Daragon","year":"1993","unstructured":"Daragon A, Humez C, Michot C, et al.: Treatment of multiple myeloma with etidronate: results of a multicentre double-blind study. Groupe d\u2019Etudes et de Recherches sur le Myelome (GERM). Eur J Med 1993, 2:449\u2013452.","journal-title":"Eur J Med"},{"key":"26_CR43","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/0140-6736(92)93075-X","volume":"340","author":"R Lahtinen","year":"1992","unstructured":"Lahtinen R, Laakso M, Palva Y, et al.: Randomized, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 1992, 340:1049\u20131052.","journal-title":"Lancet"},{"key":"26_CR44","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1046\/j.1365-2141.1998.00567.x","volume":"100","author":"EV McCloskey","year":"1998","unstructured":"McCloskey EV, MacLennan IC, Drayson MT, et al.: A randomised trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol 1998, 100:317\u2013325. Large randomized study demonstrating that clodronate is useful in the prevention of bone complications in patients with MM.","journal-title":"Br J Haematol"},{"key":"26_CR45","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1159\/000218633","volume":"18","author":"ME Heim","year":"1995","unstructured":"Heim ME, Clemens MR, Queisser W, Fessele K: Prospective randomized trial of dichloromethylene bisphosphonate (clodronate) in patients with multiple myeloma requiring treatment: a multicenter study. Onkologie 1995, 18:439\u2013448.","journal-title":"Onkologie"},{"key":"26_CR46","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1056\/NEJM199602223340802","volume":"334","author":"JR Berenson","year":"1996","unstructured":"Berenson JR, Lichtenstein A, Porter L, et al.: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996, 334:488\u2013493. Randomized study demonstrating that pamidronate reduces and delays bone complications in patients with MM.","journal-title":"N Engl J Med"},{"key":"26_CR47","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","volume":"91","author":"JR Berenson","year":"2001","unstructured":"Berenson JR, Rosen LS, Howell A, et al.: Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001, 91:1191\u20131200.","journal-title":"Cancer"},{"key":"26_CR48","first-page":"377","volume":"7","author":"LS Rosen","year":"2001","unstructured":"Rosen LS, Gordon D, Kaminski M, et al.: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, doubleblind, comparative trial. Cancer J 2001, 7:377\u2013387. Randomized study demonstrating that the use of zoledronic acid is as effective as pamidronate for the treatment of bone disease in patients with MM.","journal-title":"Cancer J"},{"key":"26_CR49","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1200\/JCO.2002.06.037","volume":"20","author":"JR Berenson","year":"2002","unstructured":"Berenson JR, Hillner BE, Kyle RA, et al.: American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002, 20:3719\u20133736. Panel of experts\u2019 recommendations for the use of bisphosphonates in patients with MM.","journal-title":"J Clin Oncol"},{"key":"26_CR50","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1046\/j.1365-2141.2002.03549.x","volume":"118","author":"A Mart\u00edn","year":"2002","unstructured":"Mart\u00edn A, Garc\u00eda-Sanz R, Hernandez J, et al.: Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect. Br J Haematol 2002, 118:239\u2013242.","journal-title":"Br J Haematol"},{"key":"26_CR51","unstructured":"British Columbia Cancer Agency Drug Index for Professionals: Clodronate. http:\/\/www.bccancer.bc.ca\/HPI\/ DrugDatabase\/DrugIndexALPro\/Clodronate.htm. Accessed February 11, 2003."},{"key":"26_CR52","unstructured":"The Zometa International site. http:\/\/www.zometa.com\/ index.html. Accessed February 11, 2003."}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-003-0026-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-003-0026-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-003-0026-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-003-0026-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T13:24:44Z","timestamp":1652621084000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-003-0026-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,6]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,6]]}},"alternative-id":["26"],"URL":"https:\/\/doi.org\/10.1007\/s11864-003-0026-7","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,6]]}}}